3 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
| Phase 1 | 1 | Terminated 1 |
Follow Myeloproliferative Diseases: new trials by email Literature Review of Myeloproliferative Diseases trials Research Report on Myeloproliferative Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) Pacritinib, Busulfan, Questionnaires - Myeloproliferative Diseases | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2015-06-15 | 2018-10-30 |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene Fludarabine, Melphalan, Alemtuzumab - Leukemia, Myeloma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2013-12-27 | 2019-07-16 |
| Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) Fludarabine, Melphalan, Alemtuzumab - Leukemia, Lymphoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 16 | 2012-02-01 | 2016-03-17 |
Hodgkin Disease (2) · Leukemia (2) · Lymphoma (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Neoplasms, Plasma Cell (2) · Graft vs Host Disease (1) · Myeloproliferative Disorders (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1) · Thrombocythemia, Essential (1)
Bone Marrow Diseases (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Hemorrhagic Disorders (3) · Neoplasms (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Hemostatic Disorders (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms by Histologic Type (2) · Paraproteinemias (2) · Vascular Diseases (2)
fludarabine (3) · fludarabine phosphate (3) · Alemtuzumab (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Melphalan (2) · Surveys and Questionnaires (2) · Tacrolimus (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · AP 1903 reagent (1) · Busulfan (1) · Methotrexate (1) · Methylprednisolone (1) · Methylprednisolone Acetate (1) · Methylprednisolone Hemisuccinate (1)
M.D. Anderson Cancer Center (3)
United States (3)
Richard E. Champlin, MD, BS (1) · Richard E. Champlin, MD,BS (1) · Uday Popat, MD (1)